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a b s t r a c t
Objective: OT was reported to be a direct regulator of bone mass in young rodents, and this
anabolic effect on bone is a peripheral action of OT. The goal of this study was to investigate
the peripheral action of oxytocin (OT) in the alveolar healing process in old female rats.
Materials and methods: Females Wistar rats (24-month-old) in permanent diestrus phase,
received two ip (12 h apart) injections of saline (NaCl 0.15 M – control group) or OT (45 mg/rat
– treated group). Seven days later, the right maxillary incisor was extracted and analyses
were performed up to 28 days of the alveolar healing process (35 days after saline or OT
administration).
Results: Calcium and phosphorus plasma concentrations did not differ between the groups.
The plasma biochemical bone formations markers, alkaline phosphatase (ALP) and osteo-
calcin were significantly higher in the treated group. Histomorphometric analyses con-
firmed bone formation as the treated group presented the highest mean value of post-
extraction bone formation. Tartrate-resistant acid phosphatase (TRAP) was significantly
reduced in the treated group indicating an anti-resorptive effect of OT. Immunohistochem-
istry reactions performed in order to identify the presence of osteocalcin and TRAP in the
bone cells of the dental socket confirmed these outcomes.
Conclusions: OT was found to promote bone formation and to inhibit bone resorption in old
acyclic female rats during the alveolar healing process.
Published by Elsevier Ltd.
Available online at www.sciencedirect.com
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Open access under the Elsevier OA license.1. Introduction
Postmenopausal osteoporosis is a systemic skeletal disease
resulting in increased bone fragility and fracture risk subse-
quent to a decrease in bone mass and the degradation of bone
microarchitecture.1,2 Despite the availability of several treat-
ment options, annual hip fracture rates are predicted to* Corresponding author at: Department of Basic Sciences, Physiology L
527, University Campus, Building 31, Arac¸atuba, Sa˜o Paulo 16018-805
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Open access under the Elsevier OA license.exceed six million by 2050 and this is a question of scientific,
social and economic importance.1,3,4 Additionally, there are
important age-related changes in the maxillofacial skeleton,
particularly in association with tooth loss and periodontal
disease. Osteoporosis and periodontal disease increase with
age and postmenopausal women without hormone replace-
ment therapy had the highest maxillary implant failure rate.5
Bone metabolism combines bone resorption (osteoclasts) andaboratory – Univ Estadual Paulista, Rodovia Marechal Rondon Km
, Brazil. Tel.: +55 18 36362757.
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humans, this balance is impaired and is mainly related to
the decrease in the secretion of ovarian steroids, due to
significant modulation of the remodelling cycle exerted by
oestrogen.6,7 Thus, the aim of treatments for osteoporosis is to
increase the density, by acting on the decrease in bone
resorption or increase in bone formation.4,8,9
Studies have been developed to find new bone formation
therapies and oxytocin (OT), a primitive neurohypophyseal
hormone, has been reported to be an anabolic bone mass
regulator.10–13 OT plasma levels are significantly lower in
postmenopausal women who develop osteoporosis than in
their healthy counterparts.12 Ovariectomized rodents with
changes in bone remodelling and consequent osteopenia,
have significantly decreased OT levels when compared with
sham-operated controls.13 In young rodents, it was verified
that deletion of OT or OT receptors (Oxtr) causes reduced bone
formation and suggested that OT is indispensable for basal
skeletal homeostasis in both sexes.13 In adult male albino rats
(150–200 g body weight) intramuscular OT injection was found
to have growth promoting effects on bone.10 Subcutaneous OT
injection reversed bone loss in eight-week-old OVX mice and
reduced marrow adiposity.12,13 Transcriptonic analysis of the
Oxtr pathway as a potential regulator of osteoblast/adipocyte
balance of human multipotent adipose-derived stem cells
(hMADS) was identified by Elabd et al.12 They verified that OT
and carbetocin (a stable OT analogue) negatively modulated
adipogenesis while promoting osteogenesis in both hMADS
cells and human bone marrow mesenchymal stromal cells. It
was found that intracerebroventricular OT infusion did not
affect serum markers of osteoblast (osteocalcin) and osteo-
clast (C-telopeptide) function, or influence ex vivo osteoblast or
osteoclast formation. However, an important finding was that
intraperitoneal injection of OT in mice increased bone mineral
density as well as osteoblast formation, and this anabolic
effect was attributed to a peripheral skeletal action of OT.13
The aim of this study was to analyze peripheral action of
OT in the alveolar bone healing process of old acyclic female
rats, 28 days after tooth extraction.
2. Materials and methods
2.1. Animals and treatment
Sixteen female Wistar rats (24-month-old) were housed in a
temperature-controlled room (22  2 8C) with a 12/12 h light/
dark cycle. Animals were provided with standard rat chow and
water ad libitum. The study protocol and all procedures
involving animals were in compliance with the principles of
laboratory animal care14 and national laws on animals, and
the study itself was authorized by the Animal Research Ethics
Committee of the Sa˜o Paulo State University, Brazil (Protocol
No. 2009-005746).
The rats underwent colpocytological examination to
determine the cycle phase. A cotton swab impregnated with
saline solution (0.15 M) was inserted in the vagina. A slide
smear was carried out and immediately analyzed using a light
microscope at 40 magnification. The estrous cycle phases
were determined according to cell quantification: epithelial,cornified and leukocytes in the colpocytological examination.
Animals in the diestrus cycle phase were divided into two
groups (8 rats in each group) and were assigned to plastic cages
(4 rats/cage). Two ip injections of saline (NaCl 0.15 M – control
group) or OT (45 mg/rat – treated group) were given with a12 h
interval between them.13
2.2. Tooth extraction
Seven days after receiving OT, the rats were anaesthetized
(Xylazine – 10 mg/kg bw/ip – Dopaser Laboratories Calier S.A.,
Barcelona, Spain; and Ketamine – 80 mg/kg bw/ip – Fort Dodge
Sau´ de Animal Ltda, Brazil) and after antisepsis (Polyvinylpyr-
rolidone iodide; Indu´ stria Quı´mica e Farmaceˆutica Rioquı´mica
Ltda, Brazil) the right maxillary incisor was luxated with the
aid of a tapered instrument and extracted with a small forceps.
The movement of extraction was smooth and followed the
curvature of the rat incisor, so that root fracture would not
occur. The atraumatic surgical technique was used, which
allows tooth extraction without postoperative complica-
tions.15 The dental sockets were sutured with silk thread
(Ethicon 4.0, Johnson and Johnson, Sa˜o Paulo, SP, Brazil). The
extractions were performed in such a way that at the end of
the experimental period it was possible to obtain pieces with
reference to a 28 day period of the alveolar healing process.
2.3. Collection of materials
At 35 days after application of OT/saline solution or 28 days
post-extraction, the animals were anaesthetized (Xylazine + -
Ketamine, as previously described), blood was collected from
the external jugular vein by cannula16 and put into a centrifuge
tube. The plasma was separated by centrifugation (3000 rpm/
10 min/1 8C). A sample was acidified with acetic acid 20% in the
proportion of 1/100 for Tartrate-resistant acid phosphatase
(TRAP) determination. Calcium, phosphorus, total alkaline
phosphatase (ALP) concentrations were determined in accor-
dance with the manufacturer’s instructions (Labtest kits, Sa˜o
Paulo, Brazil). Plasma osteocalcin and TRAP levels were
determined with a quantitative sandwich type of enzyme
linked immunoassay (ELISA) technique using rat kits pur-
chased from Uscn Life Science Inc. (Wuhan, China).
After euthanasia with an overdose of anaesthetic, the right
maxilla was removed. The pieces obtained were post fixed in
4% formaldehyde and demineralized in 10% EDTA (Merck,
Darmstadt, Germany). Using a cryostat (Micron Zeiss, Berlin,
Germany), the pieces were sliced longitudinal to the long axis
of the dental socket to obtain 06 mm thick slices, which were
mounted on previously gelatinized slides.
2.4. Histomorphometric analysis
The histomorphometric analysis of the bone mass and of the
middle thirds of the rat alveolus15,17 was performed with two
slices from each animal stained with haematoxylin and eosin
(Haloquı´mica, Sa˜o Paulo, SP, Brazil). The analyses were
performed without the examiner knowing to which group
the slices belonged. Stained sections were examined by light
microscopy under 10 objective lenses, and images were
obtained with a digital camera (JVC TK-1270 Color Video
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Qwin Color/RGB software.
2.5. Immunohistochemistry reaction
For the immunohistochemistry reactions, primary antibodies
anti osteocalcin and anti TRAP (goat anti osteocalcin polyclonal
and goat anti TRAP polyclonal – Santa Cruz Biotechnology, CA,
USA) were used, and biotinylated rabbit anti-goat antibodies
(AffiniPure rabbit anti goat IgG – Pierce Biotechnology, Rockford,
IL, USA) were the secondary antibodies. The immunohistochem-
istry reaction signal was amplifiedwith the Avidin–Biotinsystem
(Kit ABC Vectastain Elite, ABC, Vector Laboratories, Burlingame,
CA, USA) and the reaction was revealed using diaminobenzidine
(Sigma, Saint Louis, MO, USA) as the chromogen. Haematoxylin
was used for counterstaining. The analysis was performed in
order to identify the labelling characteristics of each protein
studied by this methodological approach.
2.6. Statistical methods
Differences between groups were tested using the Student’s t-
test as the criteria of normality. Equal variances betweenFig. 1 – Plasma concentrations of calcium (A), phosphorous (B), A
in the middle third of the alveoli at 28 days of healing process 
post tooth extraction) with two ip injections of saline solution 
administered with an interval of 12 h between them. Calcium a
groups. Biochemical bone formation markers (ALP and osteocal
(TRAP) decreased. Histomorphometric evaluation showed a sig
third of the alveolus. Values are means W SEM, n = 8 rats per gr
control.groups were met with a significance level of 0.05 using
GraphPad Prism 3.02 (GraphPad Software, Inc.; La Jolla, CA,
USA). All data are reported as means with their standard errors
of the mean (SEM).
3. Results
The plasma concentration of calcium (control = 10.70  0.6580;
treated = 10.41  0.6663 mg/dL) (Fig. 1A) and phosphorus (con-
trol = 4.880  0.3216; treated = 5.629  0.3932 mg/dL) (Fig. 1B)
was not significantly changed by treatment with oxytocin.
However plasmatic concentrations of biochemical bone forma-
tion markers18 ALP (control = 73.20  4.510; treated = 130.8 
11.37 U/L) (Fig. 1C) and osteocalcin (control = 0.7280  0.02956;
treated = 1.117  0.04839 ng/mL) (Fig. 1D) were significantly
increased after OT treatment. The plasmatic levels of bone
resorption marker, TRAP,18 (control = 2.404  0.3724; treated =
0.5867  0.07200 U/L) were significantly decreased (Fig. 1E) in
the treated group. At 28 days after tooth extraction, histomor-
phometric evaluation (Fig. 1F) showed a significant increase in
trabecular bone volume of the middle third of the alveoli of
treated animals (44.36  2.697%) compared with those ofLP (C), osteocalcin (D), TRAP (E) and area of bone formation
(F). Results were obtained 35 days after treatment (28 days
(0.15 M/control group) or OT (45 mg/rat/treated group)
nd phosphorous plasma levels did not differ between the
cin) increased, as the biochemical bone resorption marker
nificant increase in trabecular bone volume in the middle
oup. Statistics: Student’s t-test; P < 0.05. *Different from
Fig. 2 – Histological sections (6 mm thick) of the middle third of rat alveolus at 28 days of healing process. Results were
obtained 35 days after treatment (28 days post tooth extraction) with two ip injections of saline solution (0.15 M/control
group) or OT (45 mg/rat/treated group) administered with an interval of 12 h between them. Control (A – 100T; C – 400T; E –
1000T) showed areas with thin bone trabeculae (BT) and connective tissue (CT); osteoblasts (Ob) predominated over the
osteocytes (Os); treated (B – 100T; D – 200T; F – 1000T) showed larger amount of bone matrix with greater presence of
osteoblasts and osteocytes. Histological sections stained with haematoxylin and eosin.
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tion of the healing process in the alveolar middle third of the
control group (Fig. 2A, C, and E) showed lower bone formation in
comparison with the OT treated group (Fig. 2B, D, and F), with
much larger areas of thin bone trabeculae and areas occupied by
connective tissue. In these animals, the bone had formed
osteoblasts predominantly over the osteocytes, and trabeculae
were more isolated. In the OT treated group (Fig. 2B, D, and F)
there was a larger area of bone formation occupying most of the
interior of the alveoli. In this region, there was a large amount of
bone matrix with greater presence of osteocytes. The formationof islands of bone tissue was observed to a greater and more
developed extent, with the presence of osteoblasts and
osteocytes in greater quantity. There was presence of granula-
tion tissue to a lesser extent (presence of tissue supplied with
blood vessels, scattered collagen fibres, fibroblasts and amor-
phous ground substance). It was also found that the trabecular
bone in this group was more compact, i.e., a greater fusion of the
trabeculae when compared with the group that did not receive
OT, in which the trabeculae were found to be more isolated.
Immunohistochemistry reactions against osteocalcin and
TRAP were performed in the paraffin slices in order to identify
Fig. 3 – Histological sections (6 mm thick) of the middle third of rat alveolus at 28 days of healing process (35 days after OT
treatment) showing the osteocalcin immunolabelling. Note that in A (100T) and C (200T), almost no positive labelling for
osteocalcin either in mineralized bone matrix or in bone cells could be observed. Otherwise in B (100T) and D (200T) (treated
groups), a greater labelling of this protein was observed, showing that in the treated groups there was an increase in
mineralized bone matrix labelled with this protein, the main bone mineralization marker. Osteoblasts were also positive
for this protein.
Fig. 4 – Histological sections (6 mm thick) of the middle third of rat alveolus at 28 days of healing process (35 days after OT
treatment) showing TRAP immunolabelling. Note that in A (100T) and C (200T) (control groups), it was possible to observe a
large number of osteoclasts with positive TRAP labelling, representing an intense bone resorption activity. In B (100T) and
D (200T) (treated groups), there were no osteoclasts present close to the bone trabeculae.
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labelling showed that there was a decrease in the presence of
this protein in osteoblasts and in the mineralized matrix in the
control group (Fig. 3A and C). Indeed, in the treated group
(Fig. 3B and D), there was greater labelling of this protein
showing that the bone presented a better condition of
mineralization when compared with the control group. With
regard to TRAP labelling, there was a large quantity of
osteoclasts with positive label for this enzyme in the control
group (Fig. 4A and C), showing intense bone resorption activity
in these animals. Otherwise, in the treated groups, there was
an important decrease in the expression of cells with positive
TRAP labelling, showing that there was a less resorption
activity in the treated animals (Fig. 4B and D).
4. Discussion
These results indicate that in old female rats (24-month-old),
OT promoted increase in bone formation and decrease in bone
resorption during the alveolar bone repair process. The
mechanisms involved in this response are not fully under-
stood, but this can occur due to changes in intracellular events
essential for the development of osteoblasts and osteoclasts.
Old female rats have many interesting characteristics for
analysis of bone loss after acyclicity of the estrous cycles.19 In
this study they were subjected to tooth extraction for analysis
of the alveolar bone regeneration process, as this model may
be considered a good indicator of bone damage.17,20,21
Although the major sites of OT gene expression occur in the
central nervous system, it is also synthesized in peripheral
tissues, e.g., the uterus, placenta, amnion, corpus luteum,
testis and heart.22 Exogenous OT exerts this effect peripherally
since the neuropeptide does not cross the blood–brain
barrier.11,23 It was reported that intraperitoneal injection of
OT negatively modulated adipogenesis while promoting
osteogenesis in young rodents (3–6-month-old).11,12
The peripheral action of OT in old rats analyzed in this
study promoted significant increases in ALP and osteocalcin.
These indicate new bone formation, since ALP and osteocalcin
are excellent biochemical markers of bone formation activi-
ty.18 It has been observed that higher serum-osteocalcin levels
are relatively well correlated with increases in bone density
during treatment of osteoporosis with anabolic bone forma-
tion drugs.24 Furthermore, the ALP produced in the bone
formation phase is an excellent indicator of bone formation
activity.24 Thus, our results suggest that OT stimulates
osteoblast activity and neobone formation in old rats (24-
month-old).
Although analyses of the bone formation markers after OT
treatment signalled changes in the alveolar bone regeneration
process, histomorphometric and immunohistochemistry
analysis, considered reliable markers, were also tested. The
significant increase in alveolar bone formation and the greater
labelling of osteocalcin observed in OT treated rats suggests
that mineralization had taken place with utmost fidelity.
The immunohistochemical approach allows preservation
of the tissue cytoarchitecture, which is an important aspect to
consider when the alveolar healing process is evaluated.25,26
Osteocalcin, an indicator of bone turnover, is synthesized byosteoblasts and becomes incorporated into the bone matrix by
binding to hydroxyapatite in a calcium-dependent fash-
ion.27,28 The greater labelling of this protein in the treated
group showed that the bone presented a better condition of
mineralization when compared with the control group.
The greatest alveolar bone formation observed in our study
after OT administration could be collected from the interac-
tion of the hormone with its receptor in bone cells,29 resulting
in intracellular events, such as those described by Copland
et al.30 Thus, OT could increase the release of intracellular
calcium and prostaglandin E2 synthesis, with consequent
positive bone balance.31 The interaction between OT and Oxtr
in osteoblasts may also involve other intracellular events (MAP
kinase phosphorylation and c-Fos expression), as described in
other OT target cells.30,32 These intracellular pathways are
essential for osteoblasts and osteoclasts.
In fact the action of OT has been reported to be a direct
regulator of bone mass mediated mainly through its stimula-
tion of osteoblast formation, with variable effects on osteo-
clasts.13 Oxtr expression by fully differentiated human
osteoclasts and by their precursors has been demonstrated.33
Furthermore, it has been reported that the receptor is
functional, and that the hormone may affect osteoclastogen-
esis, since it increases the number of pre-osteoclasts.13,33
Despite the fact that OT may favour osteoclastogenesis, it
can inhibit the resorptive function of mature osteoclasts
through a calcium signalling mechanism activated by Oxtr,
since OT treatment induces an increase in intracellular
calcium.13 This could explain the significant decrease in the
levels of TRAP, a bone resorption marker,18 observed in the OT
treated rats. Osteoclast origin TRAP is presumably released
into circulation during bone resorption and after the removal
of osteoclasts from their place of work.34,35 The significant
decrease in TRAP levels after OT treatment suggests that in old
female rats oxytocin acts by inhibiting bone resorption during
the alveolar healing process. In agreement with this, the
immunohistochemical analysis against TRAP demonstrated a
greater quantity of osteoclasts with positive label for this
enzyme in the control group. Otherwise, in the treated groups,
there was an important decrease in the expression of cells
with positive TRAP labelling.
Since the interaction between oxytocin and its receptor
triggers intracellular events that are important for the
development of osteoblasts and osteoclasts, OT could be
associated with the disruption of balance between osteoblasts
and osteoclasts that causes senile and endocrine-mediated
osteoporosis.28
The positive bone balance and the decreased bone
resorption observed during the alveolar healing process of
old acyclic rats suggest that OT could be studied for use as an
ally in the recovery of dental or alveolar trauma and in
maxillary implants. Further studies with OT should explore
the possibilities of using OT as an anabolic bone hormone as
therapy for postmenopausal osteoporosis in humans.
5. Conclusion
The results presented indicate that in old acyclic female rats,
peripheral OT plays a role in achieving a positive bone balance
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process.
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